B-cell Non Hodgkin Lymphoma Clinical Trials

12 recruiting

B-cell Non Hodgkin Lymphoma Trials at a Glance

14 actively recruiting trials for b-cell non hodgkin lymphoma are listed on ClinicalTrialsFinder across 6 cities in 16 countries. The largest study group is Phase 1 with 8 trials, with the heaviest enrollment activity in Seoul, Taipei, and Kaohsiung City. Lead sponsors running b-cell non hodgkin lymphoma studies include Second Affiliated Hospital, School of Medicine, Zhejiang University, ImmunityBio, Inc., and AstraZeneca.

Browse b-cell non hodgkin lymphoma trials by phase

Treatments under study

About B-cell Non Hodgkin Lymphoma Clinical Trials

Looking for clinical trials for B-cell Non Hodgkin Lymphoma? There are currently 12 studies actively recruiting participants. Clinical trials offer access to new treatments before they are widely available, and every approved therapy in use today was first tested through a clinical trial.

Below you can browse trials, sign up for alerts when new B-cell Non Hodgkin Lymphoma trials open, and view eligibility criteria for each study. Each listing includes the study phase, locations, and enrollment details.

Frequently Asked Questions

Common questions about B-cell Non Hodgkin Lymphoma clinical trials

A clinical trial is a carefully designed research study that tests new medical treatments, drugs, devices, or approaches in human volunteers. Every approved medication and treatment available today was proven safe and effective through clinical trials.

All clinical trials are reviewed and approved by Institutional Review Boards (IRBs) — independent committees that evaluate patient safety. Trials follow strict protocols, and your health is monitored closely throughout. You can withdraw at any time.

Not necessarily. Many trials compare the new treatment against the current standard of care, meaning all participants receive active treatment. When placebos are used, they are typically combined with standard treatment, not given alone. The trial description will always specify the design.

Under the Affordable Care Act, most private insurers are required to cover routine patient care costs during a clinical trial. The sponsor typically covers the investigational treatment itself. Medicare also covers routine costs for qualifying trials.

Yes. Participation is completely voluntary. You can withdraw at any time, for any reason, without it affecting your access to standard medical care.

Each trial has specific eligibility criteria — including age, diagnosis, disease stage, prior treatments, and general health. Browse the trials listed above and check their eligibility sections. You can also contact the trial site directly to discuss your situation.

Showing 114 of 14 trials

Recruiting
Phase 1

A Study of AZD0486 in Subjects With B-Cell Non-Hodgkin Lymphoma

Diffuse Large B Cell LymphomaHigh-grade B-cell LymphomaFollicular Lymphoma+1 more
AstraZeneca227 enrolled27 locationsNCT04594642
Recruiting
Phase 1Phase 2

UCD19 CarT in Treatment of Pediatric B-ALL and B-NHL

B-cell Non Hodgkin LymphomaB-cell Acute Lymphoblastic Leukemia
University of Colorado, Denver45 enrolled1 locationNCT04544592
Recruiting
Early Phase 1

A Clinical Study Exploring the Safety, Efficacy and Metabolic Kinetics of CT1182 Injection in Patients With Relapsed / Refractory Non Hodgkin Lymphoma

DLBCL - Diffuse Large B Cell LymphomaB-cell Non Hodgkin Lymphoma (NHL)
Union Hospital, Tongji Medical College, Huazhong University of Science and Technology24 enrolled1 locationNCT07548697
Recruiting
Phase 1Phase 2

Metabolically Fit CD19 CAR T-cell Therapy With CD34 Selection in Patients With CD19+ Relapsed/Refractory NHL, CLL/SLL

Chronic Lymphocytic LeukemiaB-cell Non Hodgkin Lymphoma
Medical University of South Carolina27 enrolled1 locationNCT05702853
Recruiting
Phase 2

Study of Relapsed/ Refractory B-cell Non- Hodgkin Lymphoma

Relapsed B-Cell Non Hodgkin Lymphoma
ImmunityBio, Inc.20 enrolled2 locationsNCT07125872
Recruiting
Phase 2Phase 3

A Global Study of Novel Agents in Paediatric and Adolescent Relapsed and Refractory B-cell Non-Hodgkin Lymphoma

B-cell Non Hodgkin Lymphoma
University of Birmingham210 enrolled11 locationsNCT05991388
Recruiting
Phase 2

Pembrolizumab and Tazemetostat to Overcome Immune Tolerance Following ASCT or CAR T-cell Therapy in Patients With Aggressive B-Cell Non-Hodgkin's Lymphoma

B-cell Non Hodgkin Lymphoma
Northwestern University32 enrolled2 locationsNCT06242834
Recruiting
Phase 2

CAR-T Following ASCT for Relapsed/Refractory B-Cell Non-Hodgkin's Lymphoma (R/R B-NHL) With High-Risk Prognostic Factors

B-cell Non Hodgkin Lymphoma
Ruijin Hospital16 enrolled1 locationNCT06365671
Recruiting
Phase 1

A Study to Evaluate the Safety and Activity of SAR448501/DR-0201 in Patients With Relapsed/ Refractory B-Cell Non-Hodgkin Lymphoma

B-cell Non Hodgkin Lymphoma
Sanofi96 enrolled16 locationsNCT06392477
Recruiting
Not Applicable

Long-Term Follow-up of Patients Treated With Miltenyi Cell and Gene Therapies

Melanoma Stage IVPediatric ALLMelanoma Stage III+4 more
Miltenyi Biomedicine GmbH40 enrolled7 locationsNCT06508775
Recruiting
Phase 1

Clinical Study of Cord Blood-derived IL-10/IL-15 CD19-CAR NK in the Treatment of Refractory/Relapsed B-cell NHL

B-cell Non Hodgkin Lymphoma
Second Affiliated Hospital, School of Medicine, Zhejiang University24 enrolled1 locationNCT06707259
Recruiting
Phase 1

Clinical Study of Cord Blood-derived CAR-NK Cells Targeting CD19 in the Treatment of Refractory/Relapsed B-cell NHL

B-cell Non Hodgkin Lymphoma
Second Affiliated Hospital, School of Medicine, Zhejiang University48 enrolled1 locationNCT05472558
Recruiting
Phase 1

A Study of JMT601 in Participants With Relapsed or Refractory CD20-positive B-cell Non-Hodgkin Lymphoma

B-cell Non Hodgkin Lymphoma
Shanghai JMT-Bio Inc.186 enrolled1 locationNCT06725524
Recruiting
Phase 1Phase 2

Safety, Tolerability, and Efficacy of AT101 in Patients With Relapsed or Refractory B-cell Non-Hodgkin's Lymphoma

B-cell Non Hodgkin Lymphoma
AbClon82 enrolled1 locationNCT05338931